Cerapedics reveals 24-month ASPIRE Study results in Spine journal, showing PearlMatrix™ P-15 Peptide Bone Graft outperformed autograft with superior clinical success and time-to-fusion, with over double the patients involved.
Results from the pivotal IDE study ASPIRE revealed that PearlMatrix achieved greater clinical success and faster time-to-fusion at 24 months compared to local autograft. The study, known for its rigorous design, included over twice the number of patients. This demonstrates the superiority of PearlMatrix in terms of both clinical outcomes and efficiency in achieving fusion within the specified timeframe.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments